Casebia Therapeutics

Casebia Therapeutics, established in 2016, is a joint venture between CRISPR Therapeutics and Bayer, with both parties holding equal shares. It is committed to developing treatments for blood disorders, autoimmune diseases, metabolic conditions, and congenital heart disease through gene-editing technology. CRISPR provides Casebia with gene-editing technical support, targeting specific disease areas such as hematology and ophthalmology, while Bayer offers protein engineering technical support to significantly enhance the capabilities of the CRISPR/Cas9 gene-editing platform.